| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pelvic Inflammatory Disease | 32 | 2021 | 39 | 4.650 |
Why?
|
| Surgical Wound Infection | 22 | 2021 | 168 | 3.630 |
Why?
|
| Pregnancy Complications, Infectious | 17 | 2020 | 92 | 3.580 |
Why?
|
| Anti-Bacterial Agents | 27 | 2021 | 1026 | 2.940 |
Why?
|
| Trichomonas Vaginitis | 8 | 2022 | 25 | 2.810 |
Why?
|
| Vaginosis, Bacterial | 18 | 2020 | 24 | 2.530 |
Why?
|
| Pregnancy | 63 | 2022 | 2331 | 2.370 |
Why?
|
| Endometritis | 19 | 2021 | 29 | 2.150 |
Why?
|
| Cesarean Section | 11 | 2021 | 101 | 2.080 |
Why?
|
| Trichomonas vaginalis | 5 | 2022 | 22 | 1.850 |
Why?
|
| Sexually Transmitted Diseases | 9 | 2022 | 53 | 1.720 |
Why?
|
| Vagina | 13 | 2021 | 87 | 1.700 |
Why?
|
| Fetal Membranes, Premature Rupture | 9 | 2015 | 45 | 1.570 |
Why?
|
| Female | 139 | 2022 | 38015 | 1.430 |
Why?
|
| Chlamydia Infections | 11 | 2016 | 41 | 1.380 |
Why?
|
| Salpingitis | 5 | 2021 | 5 | 1.320 |
Why?
|
| Chlamydia trachomatis | 12 | 2016 | 26 | 1.240 |
Why?
|
| Laparoscopy | 9 | 2013 | 237 | 1.130 |
Why?
|
| Cerclage, Cervical | 4 | 2013 | 11 | 1.120 |
Why?
|
| Abscess | 2 | 2020 | 37 | 1.090 |
Why?
|
| Metronidazole | 6 | 2022 | 28 | 1.080 |
Why?
|
| Humans | 142 | 2022 | 68525 | 1.050 |
Why?
|
| Contraceptive Agents, Female | 4 | 2013 | 16 | 1.050 |
Why?
|
| Gynecologic Surgical Procedures | 5 | 2017 | 37 | 0.950 |
Why?
|
| Bacterial Infections | 10 | 2011 | 163 | 0.920 |
Why?
|
| HIV Infections | 3 | 2022 | 775 | 0.920 |
Why?
|
| Antibiotic Prophylaxis | 6 | 2021 | 62 | 0.920 |
Why?
|
| Preoperative Care | 5 | 2019 | 275 | 0.880 |
Why?
|
| Sepsis | 4 | 2015 | 233 | 0.880 |
Why?
|
| Adult | 84 | 2020 | 21375 | 0.870 |
Why?
|
| Pregnancy Complications, Parasitic | 2 | 2019 | 6 | 0.840 |
Why?
|
| Premedication | 3 | 2019 | 49 | 0.810 |
Why?
|
| Fallopian Tube Diseases | 2 | 2020 | 2 | 0.810 |
Why?
|
| Puerperal Infection | 9 | 2021 | 15 | 0.770 |
Why?
|
| Ovarian Diseases | 1 | 2020 | 7 | 0.770 |
Why?
|
| Infant, Newborn, Diseases | 4 | 2015 | 91 | 0.760 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2019 | 99 | 0.760 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 85 | 0.730 |
Why?
|
| Staphylococcal Infections | 4 | 2012 | 156 | 0.730 |
Why?
|
| Gonorrhea | 12 | 2016 | 50 | 0.710 |
Why?
|
| Uterine Myomectomy | 1 | 2019 | 1 | 0.700 |
Why?
|
| Device Removal | 2 | 2013 | 100 | 0.700 |
Why?
|
| Needlestick Injuries | 2 | 2009 | 10 | 0.690 |
Why?
|
| Needles | 2 | 2009 | 34 | 0.680 |
Why?
|
| Postoperative Care | 2 | 2019 | 163 | 0.670 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 581 | 0.670 |
Why?
|
| Intraoperative Care | 1 | 2019 | 91 | 0.660 |
Why?
|
| Chorioamnionitis | 4 | 2015 | 40 | 0.630 |
Why?
|
| Candidiasis, Vulvovaginal | 4 | 2021 | 9 | 0.620 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2013 | 35 | 0.610 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 30 | 0.590 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2007 | 9 | 0.580 |
Why?
|
| Cefoxitin | 6 | 2008 | 20 | 0.550 |
Why?
|
| Rural Population | 2 | 2018 | 397 | 0.540 |
Why?
|
| Mass Screening | 3 | 2020 | 837 | 0.530 |
Why?
|
| Cefazolin | 3 | 2021 | 19 | 0.530 |
Why?
|
| Intrauterine Devices | 2 | 2013 | 15 | 0.500 |
Why?
|
| Infection Control | 4 | 2017 | 101 | 0.490 |
Why?
|
| Risk Factors | 26 | 2020 | 5719 | 0.490 |
Why?
|
| Streptococcal Infections | 3 | 2020 | 53 | 0.480 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 445 | 0.470 |
Why?
|
| Trichomonas Infections | 3 | 2022 | 14 | 0.470 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2013 | 1 | 0.470 |
Why?
|
| Mefenamic Acid | 1 | 2013 | 1 | 0.470 |
Why?
|
| Metrorrhagia | 1 | 2013 | 3 | 0.470 |
Why?
|
| Levonorgestrel | 1 | 2013 | 6 | 0.470 |
Why?
|
| Prenatal Diagnosis | 1 | 2013 | 73 | 0.460 |
Why?
|
| Hysterectomy | 6 | 2010 | 64 | 0.460 |
Why?
|
| Neisseria gonorrhoeae | 10 | 2016 | 35 | 0.450 |
Why?
|
| Papillomavirus Infections | 4 | 2014 | 163 | 0.450 |
Why?
|
| Pelvic Infection | 1 | 2012 | 1 | 0.450 |
Why?
|
| Reproductive Tract Infections | 1 | 2012 | 3 | 0.450 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 69 | 0.450 |
Why?
|
| Tamoxifen | 1 | 2013 | 62 | 0.450 |
Why?
|
| Bacteremia | 2 | 2012 | 155 | 0.450 |
Why?
|
| Tranexamic Acid | 1 | 2013 | 37 | 0.450 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2012 | 92 | 0.450 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 52 | 0.440 |
Why?
|
| Postoperative Complications | 8 | 2010 | 1615 | 0.430 |
Why?
|
| Vulvar Diseases | 3 | 2008 | 4 | 0.430 |
Why?
|
| Pelvic Pain | 5 | 2005 | 11 | 0.430 |
Why?
|
| Doxycycline | 5 | 2008 | 49 | 0.430 |
Why?
|
| Gloves, Surgical | 2 | 2009 | 5 | 0.420 |
Why?
|
| Clostridium perfringens | 1 | 2011 | 3 | 0.420 |
Why?
|
| Sutures | 2 | 2013 | 32 | 0.420 |
Why?
|
| Methicillin Resistance | 2 | 2010 | 45 | 0.420 |
Why?
|
| Clostridium Infections | 2 | 2011 | 52 | 0.410 |
Why?
|
| Cohort Studies | 9 | 2020 | 2356 | 0.410 |
Why?
|
| Infant, Newborn | 15 | 2022 | 2453 | 0.410 |
Why?
|
| Betamethasone | 5 | 2001 | 24 | 0.400 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 239 | 0.390 |
Why?
|
| Anti-Infective Agents | 5 | 2010 | 166 | 0.390 |
Why?
|
| Genital Diseases, Female | 4 | 1999 | 23 | 0.360 |
Why?
|
| Prospective Studies | 24 | 2012 | 3702 | 0.360 |
Why?
|
| Amniotic Fluid | 3 | 2000 | 30 | 0.360 |
Why?
|
| Biomedical Research | 1 | 2013 | 310 | 0.350 |
Why?
|
| Retrospective Studies | 10 | 2021 | 7264 | 0.350 |
Why?
|
| Norpregnadienes | 2 | 2019 | 3 | 0.350 |
Why?
|
| Nonprescription Drugs | 2 | 2007 | 28 | 0.350 |
Why?
|
| Glucocorticoids | 5 | 2001 | 222 | 0.350 |
Why?
|
| Leiomyoma | 3 | 2019 | 28 | 0.350 |
Why?
|
| Uterine Neoplasms | 3 | 2019 | 99 | 0.340 |
Why?
|
| Attitude of Health Personnel | 3 | 2017 | 442 | 0.340 |
Why?
|
| Lacerations | 1 | 2008 | 13 | 0.330 |
Why?
|
| Antifungal Agents | 2 | 2007 | 108 | 0.330 |
Why?
|
| Shock, Septic | 2 | 2012 | 101 | 0.330 |
Why?
|
| Laparotomy | 3 | 2009 | 65 | 0.330 |
Why?
|
| Endometrium | 4 | 2006 | 31 | 0.330 |
Why?
|
| Suture Techniques | 1 | 2008 | 75 | 0.320 |
Why?
|
| Cross Infection | 1 | 2010 | 195 | 0.320 |
Why?
|
| Ambulatory Care | 4 | 2020 | 339 | 0.320 |
Why?
|
| Clostridium sordellii | 1 | 2007 | 4 | 0.320 |
Why?
|
| Abortion, Therapeutic | 1 | 2007 | 5 | 0.320 |
Why?
|
| Streptococcus agalactiae | 3 | 2020 | 26 | 0.290 |
Why?
|
| Pharmaceutical Services | 1 | 2007 | 47 | 0.290 |
Why?
|
| Bacteriuria | 1 | 2006 | 7 | 0.290 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2006 | 15 | 0.280 |
Why?
|
| Pregnancy Complications | 2 | 2004 | 286 | 0.280 |
Why?
|
| Sickle Cell Trait | 1 | 2006 | 24 | 0.280 |
Why?
|
| Mass Vaccination | 1 | 2006 | 7 | 0.280 |
Why?
|
| Alphapapillomavirus | 1 | 2006 | 15 | 0.280 |
Why?
|
| Clindamycin | 4 | 1993 | 25 | 0.270 |
Why?
|
| Obstetrics | 1 | 2006 | 44 | 0.270 |
Why?
|
| Gynecology | 1 | 2006 | 46 | 0.270 |
Why?
|
| Adolescent | 27 | 2020 | 8903 | 0.270 |
Why?
|
| Communicable Diseases | 1 | 2006 | 49 | 0.270 |
Why?
|
| Incidence | 7 | 2010 | 1582 | 0.260 |
Why?
|
| Candida albicans | 2 | 2021 | 38 | 0.260 |
Why?
|
| Papillomavirus Vaccines | 1 | 2006 | 82 | 0.260 |
Why?
|
| Health Care Surveys | 1 | 2006 | 239 | 0.260 |
Why?
|
| Pneumonia | 1 | 2005 | 110 | 0.250 |
Why?
|
| Prevalence | 5 | 2020 | 1609 | 0.250 |
Why?
|
| Body Fluids | 1 | 2004 | 41 | 0.250 |
Why?
|
| Abdomen | 5 | 2013 | 80 | 0.250 |
Why?
|
| Adnexal Diseases | 1 | 2004 | 2 | 0.240 |
Why?
|
| Prenatal Care | 2 | 2001 | 117 | 0.240 |
Why?
|
| Uterine Hemorrhage | 2 | 2018 | 16 | 0.240 |
Why?
|
| Rectum | 2 | 2001 | 62 | 0.240 |
Why?
|
| Administration, Oral | 4 | 2019 | 411 | 0.230 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 1533 | 0.230 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2014 | 285 | 0.230 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 3 | 2001 | 46 | 0.230 |
Why?
|
| Length of Stay | 5 | 2021 | 780 | 0.230 |
Why?
|
| Cervix Uteri | 5 | 2004 | 64 | 0.220 |
Why?
|
| Contraceptive Devices, Female | 2 | 1993 | 3 | 0.220 |
Why?
|
| Bacteria | 3 | 2011 | 193 | 0.220 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2013 | 58 | 0.220 |
Why?
|
| Pregnancy Outcome | 4 | 2009 | 157 | 0.220 |
Why?
|
| Uterine Cervicitis | 3 | 2014 | 18 | 0.210 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 3256 | 0.210 |
Why?
|
| United States | 16 | 2022 | 7335 | 0.210 |
Why?
|
| Double-Blind Method | 9 | 2019 | 1737 | 0.210 |
Why?
|
| South Carolina | 5 | 2018 | 2750 | 0.210 |
Why?
|
| Urinary Tract Infections | 2 | 2001 | 71 | 0.210 |
Why?
|
| Premature Birth | 2 | 2022 | 148 | 0.210 |
Why?
|
| Treatment Outcome | 11 | 2019 | 7028 | 0.210 |
Why?
|
| Middle Aged | 18 | 2020 | 21119 | 0.200 |
Why?
|
| Women's Health | 3 | 2020 | 148 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2018 | 2004 | 0.200 |
Why?
|
| Macrolides | 1 | 2021 | 48 | 0.200 |
Why?
|
| Delivery, Obstetric | 4 | 2008 | 58 | 0.200 |
Why?
|
| Salvage Therapy | 1 | 2001 | 82 | 0.200 |
Why?
|
| Sensitivity and Specificity | 7 | 2013 | 1753 | 0.200 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 648 | 0.200 |
Why?
|
| Cephalosporins | 3 | 2010 | 59 | 0.200 |
Why?
|
| Urinalysis | 1 | 2001 | 27 | 0.200 |
Why?
|
| Streptococcal Vaccines | 1 | 2020 | 2 | 0.190 |
Why?
|
| Sexual Behavior | 2 | 2021 | 179 | 0.190 |
Why?
|
| Penicillin G Benzathine | 1 | 2000 | 3 | 0.190 |
Why?
|
| Time Factors | 8 | 2016 | 4655 | 0.190 |
Why?
|
| HIV Seronegativity | 1 | 2020 | 10 | 0.190 |
Why?
|
| Penicillins | 1 | 2000 | 32 | 0.190 |
Why?
|
| Vaginitis | 4 | 2014 | 21 | 0.190 |
Why?
|
| Fetal Diseases | 1 | 2000 | 64 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2006 | 596 | 0.180 |
Why?
|
| Logistic Models | 6 | 2019 | 1419 | 0.180 |
Why?
|
| Texas | 2 | 2010 | 92 | 0.180 |
Why?
|
| Gentamicins | 2 | 1998 | 68 | 0.180 |
Why?
|
| Acute Disease | 6 | 2011 | 658 | 0.170 |
Why?
|
| Drug Administration Schedule | 7 | 2010 | 567 | 0.170 |
Why?
|
| Hospitals, Urban | 2 | 1996 | 46 | 0.170 |
Why?
|
| Cystitis | 2 | 2011 | 18 | 0.170 |
Why?
|
| Pyelonephritis | 2 | 2011 | 17 | 0.170 |
Why?
|
| Disease Management | 1 | 2020 | 248 | 0.170 |
Why?
|
| Vaccination | 2 | 2013 | 182 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2011 | 929 | 0.170 |
Why?
|
| Postmenopause | 1 | 1999 | 92 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1745 | 0.160 |
Why?
|
| North Carolina | 1 | 2019 | 224 | 0.160 |
Why?
|
| CA-125 Antigen | 1 | 1998 | 5 | 0.160 |
Why?
|
| Actinomycosis | 1 | 1998 | 6 | 0.160 |
Why?
|
| Otitis Media | 1 | 1998 | 35 | 0.160 |
Why?
|
| Puerperal Disorders | 2 | 2011 | 20 | 0.160 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 1998 | 43 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2011 | 1139 | 0.150 |
Why?
|
| Equipment Design | 2 | 2009 | 500 | 0.150 |
Why?
|
| Infertility, Female | 4 | 2008 | 25 | 0.150 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 5 | 0.150 |
Why?
|
| Genitalia, Female | 2 | 1994 | 19 | 0.150 |
Why?
|
| Hospitalization | 4 | 2010 | 977 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 766 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 1998 | 91 | 0.150 |
Why?
|
| Hospitals, Teaching | 2 | 1996 | 65 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 25 | 0.140 |
Why?
|
| Neuraminidase | 1 | 2016 | 36 | 0.140 |
Why?
|
| Professional Role | 1 | 2017 | 80 | 0.140 |
Why?
|
| Infusions, Intravenous | 4 | 2008 | 334 | 0.140 |
Why?
|
| Antitrichomonal Agents | 2 | 2007 | 5 | 0.140 |
Why?
|
| Recurrence | 7 | 2021 | 948 | 0.140 |
Why?
|
| Microbiota | 1 | 2016 | 79 | 0.130 |
Why?
|
| Young Adult | 6 | 2020 | 5708 | 0.130 |
Why?
|
| Infant | 2 | 2020 | 2891 | 0.130 |
Why?
|
| Leukorrhea | 2 | 2013 | 6 | 0.130 |
Why?
|
| Patient Safety | 1 | 2017 | 202 | 0.130 |
Why?
|
| Inflammation | 1 | 2021 | 1030 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 1995 | 141 | 0.130 |
Why?
|
| Herpes Simplex | 2 | 2012 | 35 | 0.130 |
Why?
|
| Bacterial Proteins | 2 | 2008 | 244 | 0.130 |
Why?
|
| Cellulitis | 2 | 2012 | 13 | 0.130 |
Why?
|
| Quality of Life | 3 | 2019 | 1515 | 0.120 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 455 | 0.120 |
Why?
|
| Therapeutic Irrigation | 3 | 2003 | 63 | 0.120 |
Why?
|
| Vaginal Smears | 3 | 2009 | 78 | 0.120 |
Why?
|
| Physical Examination | 2 | 2012 | 152 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 1993 | 36 | 0.120 |
Why?
|
| Papillomaviridae | 1 | 2014 | 87 | 0.120 |
Why?
|
| Laminaria | 1 | 2013 | 3 | 0.110 |
Why?
|
| Dilatation and Curettage | 1 | 2013 | 5 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 56 | 0.110 |
Why?
|
| Streptococcus pyogenes | 1 | 2012 | 20 | 0.110 |
Why?
|
| Amenorrhea | 2 | 2018 | 16 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2013 | 79 | 0.110 |
Why?
|
| Reference Values | 2 | 2008 | 579 | 0.110 |
Why?
|
| Ofloxacin | 1 | 1992 | 15 | 0.110 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2012 | 34 | 0.110 |
Why?
|
| Ceftizoxime | 1 | 1992 | 3 | 0.110 |
Why?
|
| Abdominal Pain | 2 | 1998 | 97 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2012 | 122 | 0.110 |
Why?
|
| Simplexvirus | 2 | 2012 | 26 | 0.110 |
Why?
|
| Tuberculosis, Miliary | 1 | 1992 | 2 | 0.110 |
Why?
|
| Leukocytosis | 1 | 2011 | 13 | 0.110 |
Why?
|
| Biomarkers | 1 | 1998 | 1593 | 0.110 |
Why?
|
| Consensus | 3 | 2017 | 211 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2003 | 226 | 0.100 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2011 | 35 | 0.100 |
Why?
|
| Obstetric Labor, Premature | 1 | 2012 | 76 | 0.100 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2008 | 22 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2004 | 121 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 772 | 0.100 |
Why?
|
| Douglas' Pouch | 1 | 1991 | 2 | 0.100 |
Why?
|
| Mycoplasma genitalium | 1 | 2011 | 4 | 0.100 |
Why?
|
| Probability | 2 | 2008 | 244 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2012 | 249 | 0.100 |
Why?
|
| Placenta | 1 | 2011 | 101 | 0.100 |
Why?
|
| Mycoplasma Infections | 1 | 2011 | 40 | 0.100 |
Why?
|
| Cross-Sectional Studies | 5 | 2013 | 2264 | 0.100 |
Why?
|
| Health Personnel | 1 | 2013 | 286 | 0.100 |
Why?
|
| Probenecid | 2 | 2008 | 10 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4843 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 2798 | 0.090 |
Why?
|
| Antibodies, Bacterial | 2 | 2008 | 90 | 0.090 |
Why?
|
| Aged | 5 | 2020 | 14842 | 0.090 |
Why?
|
| Pre-Eclampsia | 1 | 2011 | 202 | 0.090 |
Why?
|
| Colposcopy | 1 | 2009 | 20 | 0.090 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2009 | 44 | 0.090 |
Why?
|
| Papanicolaou Test | 1 | 2009 | 54 | 0.090 |
Why?
|
| Biopsy | 2 | 2007 | 539 | 0.090 |
Why?
|
| Consumer Behavior | 1 | 2009 | 68 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 201 | 0.080 |
Why?
|
| Accidents, Occupational | 1 | 2008 | 16 | 0.080 |
Why?
|
| Equipment Safety | 1 | 2008 | 50 | 0.080 |
Why?
|
| Injections, Intramuscular | 2 | 2005 | 44 | 0.080 |
Why?
|
| Chaperonin 60 | 1 | 2008 | 10 | 0.080 |
Why?
|
| Labor, Obstetric | 1 | 1988 | 23 | 0.080 |
Why?
|
| Episiotomy | 2 | 1989 | 2 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 481 | 0.080 |
Why?
|
| Gardnerella vaginalis | 2 | 2004 | 2 | 0.080 |
Why?
|
| Disease Susceptibility | 2 | 2006 | 179 | 0.080 |
Why?
|
| Tinidazole | 1 | 2007 | 2 | 0.080 |
Why?
|
| Hysterectomy, Vaginal | 1 | 1987 | 4 | 0.080 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 50 | 0.080 |
Why?
|
| Polyethylene Terephthalates | 1 | 2007 | 29 | 0.080 |
Why?
|
| Gestational Age | 3 | 2012 | 389 | 0.080 |
Why?
|
| Umbilical Cord | 1 | 2007 | 19 | 0.080 |
Why?
|
| Fetal Death | 1 | 2007 | 49 | 0.080 |
Why?
|
| Constriction | 1 | 2007 | 37 | 0.080 |
Why?
|
| Uterine Diseases | 1 | 1987 | 7 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 175 | 0.080 |
Why?
|
| Delayed-Action Preparations | 1 | 2007 | 120 | 0.070 |
Why?
|
| Gas Gangrene | 1 | 1986 | 3 | 0.070 |
Why?
|
| Trimethoprim | 1 | 1986 | 8 | 0.070 |
Why?
|
| Sulfamethoxazole | 1 | 1986 | 15 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2017 | 657 | 0.070 |
Why?
|
| Pharyngitis | 1 | 1986 | 10 | 0.070 |
Why?
|
| DNA, Bacterial | 1 | 2007 | 150 | 0.070 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 159 | 0.070 |
Why?
|
| Legionnaires' Disease | 1 | 1986 | 11 | 0.070 |
Why?
|
| Condylomata Acuminata | 1 | 2006 | 12 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 492 | 0.070 |
Why?
|
| Hemolysis | 1 | 1985 | 39 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2005 | 19 | 0.070 |
Why?
|
| Transferrin-Binding Protein A | 1 | 2005 | 1 | 0.070 |
Why?
|
| Transferrin-Binding Protein B | 1 | 2005 | 1 | 0.070 |
Why?
|
| Transfusion Reaction | 1 | 1985 | 33 | 0.070 |
Why?
|
| Gram-Positive Bacteria | 1 | 2005 | 23 | 0.070 |
Why?
|
| Infant, Premature | 3 | 2012 | 284 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 55 | 0.070 |
Why?
|
| Community-Acquired Infections | 1 | 2005 | 46 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2005 | 55 | 0.070 |
Why?
|
| Vaginal Douching | 1 | 2005 | 3 | 0.070 |
Why?
|
| Patient Compliance | 4 | 2009 | 402 | 0.070 |
Why?
|
| Mycoses | 1 | 2005 | 60 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1987 | 234 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2007 | 1329 | 0.060 |
Why?
|
| Fever | 1 | 1985 | 96 | 0.060 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2004 | 10 | 0.060 |
Why?
|
| Male | 8 | 2022 | 37281 | 0.060 |
Why?
|
| Patient Care Team | 2 | 2017 | 311 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2005 | 182 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2001 | 39 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2006 | 204 | 0.060 |
Why?
|
| Condoms | 1 | 2004 | 67 | 0.060 |
Why?
|
| Bacteria, Anaerobic | 2 | 2003 | 15 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 2 | 2001 | 70 | 0.060 |
Why?
|
| Fluconazole | 1 | 2003 | 26 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2004 | 223 | 0.060 |
Why?
|
| Critical Care | 1 | 2005 | 263 | 0.060 |
Why?
|
| Administration, Intravaginal | 3 | 2006 | 11 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2006 | 346 | 0.060 |
Why?
|
| Cephamycins | 1 | 2002 | 10 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2005 | 154 | 0.050 |
Why?
|
| Self Medication | 1 | 2002 | 25 | 0.050 |
Why?
|
| Candida | 1 | 2021 | 15 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2006 | 1341 | 0.050 |
Why?
|
| Adnexa Uteri | 1 | 2001 | 2 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2020 | 8 | 0.050 |
Why?
|
| Body Temperature | 2 | 2017 | 116 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 1995 | 221 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2000 | 77 | 0.050 |
Why?
|
| Immunization | 1 | 2020 | 86 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2020 | 50 | 0.050 |
Why?
|
| Hepatitis B | 1 | 2000 | 42 | 0.050 |
Why?
|
| Outpatients | 1 | 2020 | 127 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2000 | 154 | 0.040 |
Why?
|
| Health Behavior | 1 | 2003 | 458 | 0.040 |
Why?
|
| Data Collection | 2 | 2017 | 420 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2018 | 33 | 0.040 |
Why?
|
| Prognosis | 3 | 2000 | 2093 | 0.040 |
Why?
|
| Endometriosis | 1 | 1998 | 56 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 260 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 1998 | 49 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2000 | 264 | 0.040 |
Why?
|
| Contraceptives, Oral | 1 | 1997 | 28 | 0.040 |
Why?
|
| Postpartum Hemorrhage | 1 | 2016 | 12 | 0.040 |
Why?
|
| Serologic Tests | 2 | 2008 | 46 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2017 | 40 | 0.040 |
Why?
|
| Organizational Policy | 1 | 2017 | 42 | 0.040 |
Why?
|
| Organizational Culture | 1 | 2017 | 59 | 0.040 |
Why?
|
| Pregnancy, Ectopic | 2 | 1998 | 16 | 0.040 |
Why?
|
| Random Allocation | 2 | 1988 | 442 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 93 | 0.040 |
Why?
|
| Treatment Failure | 1 | 1996 | 216 | 0.030 |
Why?
|
| Connective Tissue | 1 | 1995 | 61 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2008 | 328 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 235 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1995 | 104 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 1998 | 503 | 0.030 |
Why?
|
| Child | 1 | 2006 | 6400 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2001 | 1046 | 0.030 |
Why?
|
| Risk | 2 | 2004 | 563 | 0.030 |
Why?
|
| Vulva | 2 | 1991 | 6 | 0.030 |
Why?
|
| Endoscopy | 1 | 1998 | 464 | 0.030 |
Why?
|
| Cefotaxime | 1 | 1993 | 7 | 0.030 |
Why?
|
| Tanzania | 1 | 2014 | 35 | 0.030 |
Why?
|
| Research Design | 1 | 1998 | 729 | 0.030 |
Why?
|
| Ointments | 1 | 1993 | 15 | 0.030 |
Why?
|
| Coinfection | 1 | 2014 | 29 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 424 | 0.030 |
Why?
|
| Superior Mesenteric Artery Syndrome | 1 | 1993 | 2 | 0.030 |
Why?
|
| Remission Induction | 1 | 1993 | 111 | 0.030 |
Why?
|
| Parasitology | 1 | 2013 | 4 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 2013 | 25 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 1993 | 33 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 21 | 0.030 |
Why?
|
| Parity | 2 | 1991 | 71 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 737 | 0.030 |
Why?
|
| Body Weight | 1 | 1995 | 554 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2012 | 11 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 1465 | 0.030 |
Why?
|
| Microscopy | 1 | 2013 | 64 | 0.030 |
Why?
|
| Urogenital System | 1 | 1992 | 6 | 0.030 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2012 | 15 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1992 | 29 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2005 | 242 | 0.030 |
Why?
|
| Herpes Genitalis | 1 | 2012 | 12 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2006 | 1054 | 0.030 |
Why?
|
| Skin | 1 | 1995 | 451 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1992 | 193 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2005 | 880 | 0.030 |
Why?
|
| Body Mass Index | 1 | 1995 | 866 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 618 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1992 | 65 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 113 | 0.020 |
Why?
|
| Povidone-Iodine | 1 | 1991 | 16 | 0.020 |
Why?
|
| Suction | 1 | 1991 | 33 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 1991 | 95 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2012 | 159 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2012 | 211 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 98 | 0.020 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2009 | 4 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 1992 | 225 | 0.020 |
Why?
|
| Abortion, Habitual | 1 | 2009 | 13 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1989 | 94 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 1851 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1989 | 83 | 0.020 |
Why?
|
| Professional Practice | 1 | 2009 | 47 | 0.020 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2009 | 33 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 2 | 2001 | 198 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 439 | 0.020 |
Why?
|
| Amikacin | 1 | 1988 | 13 | 0.020 |
Why?
|
| Lichen Planus | 1 | 1988 | 17 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1989 | 219 | 0.020 |
Why?
|
| Urban Population | 1 | 2009 | 254 | 0.020 |
Why?
|
| Cefonicid | 1 | 1987 | 2 | 0.020 |
Why?
|
| Cefamandole | 1 | 1987 | 5 | 0.020 |
Why?
|
| Tissue Adhesions | 1 | 1987 | 21 | 0.020 |
Why?
|
| Ibuprofen | 1 | 1987 | 30 | 0.020 |
Why?
|
| Penicillinase | 1 | 1986 | 3 | 0.020 |
Why?
|
| Phenazines | 1 | 2006 | 2 | 0.020 |
Why?
|
| Gentian Violet | 1 | 2006 | 6 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1987 | 99 | 0.020 |
Why?
|
| Rabbits | 1 | 1987 | 509 | 0.020 |
Why?
|
| Gels | 1 | 2006 | 55 | 0.020 |
Why?
|
| Muscles | 1 | 1986 | 158 | 0.020 |
Why?
|
| Erythromycin | 1 | 1986 | 13 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 244 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2006 | 144 | 0.020 |
Why?
|
| Education | 1 | 2006 | 83 | 0.020 |
Why?
|
| Necrosis | 1 | 1986 | 239 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 1985 | 37 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 791 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 1037 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1986 | 304 | 0.020 |
Why?
|
| Urethra | 1 | 2005 | 56 | 0.020 |
Why?
|
| Urban Health | 1 | 2005 | 49 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2005 | 218 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2006 | 291 | 0.020 |
Why?
|
| Safe Sex | 1 | 2004 | 24 | 0.020 |
Why?
|
| Contraception | 1 | 2004 | 27 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 378 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1860 | 0.020 |
Why?
|
| Morbidity | 1 | 2004 | 130 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 848 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 710 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 273 | 0.010 |
Why?
|
| Mobiluncus | 1 | 2003 | 1 | 0.010 |
Why?
|
| Mycoplasma hominis | 1 | 2003 | 1 | 0.010 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2003 | 2 | 0.010 |
Why?
|
| Gram-Negative Anaerobic Bacteria | 1 | 2003 | 3 | 0.010 |
Why?
|
| Colorado | 1 | 2003 | 26 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2003 | 46 | 0.010 |
Why?
|
| Boston | 1 | 2003 | 35 | 0.010 |
Why?
|
| Alabama | 1 | 2003 | 98 | 0.010 |
Why?
|
| Virginia | 2 | 1992 | 45 | 0.010 |
Why?
|
| Pregnancy Rate | 1 | 2002 | 14 | 0.010 |
Why?
|
| Drug Labeling | 1 | 2002 | 32 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 215 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 392 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2001 | 149 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1663 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 1425 | 0.010 |
Why?
|
| Retreatment | 1 | 2000 | 59 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2000 | 36 | 0.010 |
Why?
|
| Health Education | 1 | 2003 | 279 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 392 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 955 | 0.010 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 1999 | 4 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 219 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1997 | 100 | 0.010 |
Why?
|
| Patient Selection | 1 | 1998 | 592 | 0.010 |
Why?
|
| Novobiocin | 1 | 1992 | 6 | 0.010 |
Why?
|
| Coagulase | 1 | 1992 | 14 | 0.010 |
Why?
|
| Female Urogenital Diseases | 1 | 1992 | 5 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1997 | 1548 | 0.010 |
Why?
|
| Seasons | 1 | 1992 | 129 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1991 | 7 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1991 | 21 | 0.010 |
Why?
|
| Animals | 1 | 1987 | 20877 | 0.010 |
Why?
|
| Pruritus Vulvae | 1 | 1988 | 2 | 0.010 |
Why?
|
| Atrophy | 1 | 1988 | 112 | 0.010 |
Why?
|